Your browser doesn't support javascript.
SARS-CoV-2 herd immunity of the Kyrgyz population in 2021.
Popova, Anna Y; Kasymov, Omor T; Smolenski, Vyacheslav Y; Smirnov, Vyacheslav S; Egorova, Svetlana A; Nurmatov, Zuridin S; Milichkina, Anzhelika M; Suranbaeva, Gulmira S; Kuchuk, Tatiana E; Khamitova, Irina V; Zueva, Elena V; Ivanov, Valery A; Nuridinova, Zhanylai N; Derkenbaeva, Aisuluu A; Drobyshevskaya, Victoria G; Sattarova, Gulsun Z; Kaliev, Marat T; Gubanova, Alexandra V; Zhimbaeva, Oyuna B; Razumovskaya, Alexandra P; Verbov, Vyacheslav N; Likhachev, Ivan V; Krasnov, Alexey V; Totolian, Areg A.
  • Popova AY; Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Kasymov OT; Preventive Medicine Research and Production Association, Kyrgyz Ministry of Health and Social Development, Bishkek, Kyrgyzstan.
  • Smolenski VY; Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
  • Smirnov VS; Saint Petersburg Pasteur Institute, St. Petersburg, Russia. vssmi@mail.ru.
  • Egorova SA; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Nurmatov ZS; Preventive Medicine Research and Production Association, Kyrgyz Ministry of Health and Social Development, Bishkek, Kyrgyzstan.
  • Milichkina AM; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Suranbaeva GS; Preventive Medicine Research and Production Association, Kyrgyz Ministry of Health and Social Development, Bishkek, Kyrgyzstan.
  • Kuchuk TE; Preventive Medicine Research and Production Association, Kyrgyz Ministry of Health and Social Development, Bishkek, Kyrgyzstan.
  • Khamitova IV; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Zueva EV; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Ivanov VA; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Nuridinova ZN; Preventive Medicine Research and Production Association, Kyrgyz Ministry of Health and Social Development, Bishkek, Kyrgyzstan.
  • Derkenbaeva AA; Preventive Medicine Research and Production Association, Kyrgyz Ministry of Health and Social Development, Bishkek, Kyrgyzstan.
  • Drobyshevskaya VG; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Sattarova GZ; Preventive Medicine Research and Production Association, Kyrgyz Ministry of Health and Social Development, Bishkek, Kyrgyzstan.
  • Kaliev MT; Preventive Medicine Research and Production Association, Kyrgyz Ministry of Health and Social Development, Bishkek, Kyrgyzstan.
  • Gubanova AV; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Zhimbaeva OB; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Razumovskaya AP; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Verbov VN; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Likhachev IV; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Krasnov AV; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
  • Totolian AA; Saint Petersburg Pasteur Institute, St. Petersburg, Russia.
Med Microbiol Immunol ; 211(4): 195-210, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1919783
ABSTRACT
In the fight against coronavirus infection, control of the immune response is of decisive importance, an important component of which is the seroprevalence of antibodies to SARS-CoV-2. Immunity to SARS-CoV-2 is formed either naturally or artificially through vaccination. The purpose of this study was to assess the seroprevalence of antibodies to SARS-CoV-2 in the population of Kyrgyzstan. A cross-sectional randomized study of seroprevalence was carried out according to a program developed by Rospotrebnadzor and the St. Petersburg Pasteur Institute, taking into account WHO recommendations. The ethics committees of the Association of Preventive Medicine (Kyrgyzstan) and the St. Petersburg Pasteur Institute (Russia) approved the study. Volunteers (9471) were recruited, representing 0.15% (95% CI 0.14-0.15) of the total population, randomized by age and region. Plasma antibodies (Abs) to the nucleocapsid antigen (Nag) were determined. In vaccinated individuals, Abs to the SARS-CoV-2 receptor-binding domain antigen (RBDag) were determined. Differences were considered statistically significant at p < 0.05. The SARS-CoV-2 Nag Ab seroprevalence was 48.7% (95% CI 47.7-49.7), with a maximum in the 60-69 age group [59.2% (95% CI 56.6-61.7)] and a minimum in group 1-17 years old [32.7% (95 CI 29.4-36.1)]. The highest proportion of seropositive individuals was in the Naryn region [53.3% (95% CI 49.8-56.8)]. The lowest share was in Osh City [38.1% (95% CI 32.6-43.9)]. The maximum SARS-CoV-2 Nag seropositivity was found in the health-care sector [57.1% (95% CI 55.4-58.8)]; the minimum was seen among artists [38.6% (95% CI 26.0-52.4)]. Asymptomatic SARS-CoV-2 Nag seropositivity was 77.1% (95% CI 75.6-78.5). Vaccination with Sputnik V or Sinopharm produced comparable Ab seroprevalence. SARS-CoV-2 Nag seropositivity in the Kyrgyz population was 48.75% (95% CI 47.7-49.7), with the mass vaccination campaign undoubtedly benefitting the overall situation.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunity, Herd / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Child / Child, preschool / Humans / Infant Country/Region as subject: Asia / Europa Language: English Journal: Med Microbiol Immunol Year: 2022 Document Type: Article Affiliation country: S00430-022-00744-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunity, Herd / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Child / Child, preschool / Humans / Infant Country/Region as subject: Asia / Europa Language: English Journal: Med Microbiol Immunol Year: 2022 Document Type: Article Affiliation country: S00430-022-00744-7